IRCT20201124049480N1已完成3 期
Evaluation of Levamisole efficacy in treatment of COVID-19 and comparing it to the ?common treatment: a Clinical Trial
Artesh University of Medical Sciences0 个研究点目标入组 365 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 365
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Age 18 years or older
- •Positive RT PCR test for COVID-19
- •Full consent and acceptance of the patient or his companion for taking the drug
- •Patient traceability
- •Women should not become pregnant for 30 days after the end of the study
- •patients should not take levamisole for five days before entering the study (because the half-life of ?the drug is 16 hours)
排除标准
- •Another justifying cause (such as a bacterial or fungal infection) for the patient's symptoms
- •Allergic reaction to levamisole
- •Use of antibiotics other than those used to treat COVID-19
- •Shortness of breath due to cardiogenic pulmonary edema
- •Patients with unstable hemodynamics;
- •History of cirrhosis, hepatitis, or severe liver disease,
- •GFR ?less than 30 ml/min
- •Patients receiving chemotherapy for cancer
研究者
相似试验
招募中
2 期
Evaluation of Levamisole efficacy in treatment of Covid-19IRCT20190810044500N7Yazd University of Medical Sciences50
进行中（未招募）
1 期
AEUCTR2016-002324-92-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)156
已完成
3 期
The role of levamisole co-administration hepatitis B vaccine in immunization.eed for immunization against viral hepatitis.Persons with potential health hazards related to communicable diseasesIRCT2014110618915N2Mashad University of Medical Sciences217
进行中（未招募）
不适用
Traitement par lévamisole du syndrome néphrotique corticosensible de l'enfant - LEVAMISOLEenfants présentant un SNI à rechutes fréquentes ou corticodépendant, le patient sera inclus à l'occasion d'une nouvelle rechute mais une fois la rémission obtenue après reprise de la corticothérapie à 60mg/m2/j.MedDRA version: 8.1Level: PTClassification code 10029164Term: nephrotic syndromeEUCTR2005-005745-18-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
招募中
不适用
evamizole in treatment of COVID19.IRCT20181208041886N1Esfahan University of Medical Sciences60